Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?

J Thromb Haemost. 2024 Feb 28:S1538-7836(24)00115-6. doi: 10.1016/j.jtha.2024.02.013. Online ahead of print.ABSTRACTCoagulopathy alongside micro- and macrovascular thrombotic events were frequent characteristics of patients presenting with acute COVID-19 during the initial stages of the pandemic. However, over the past 4 years, the incidence and manifestations of COVID-19-associated coagulopathy have changed due to immunity from natural infection and vaccination, and the appearance of new SARS-CoV-2 variants. Diagnostic criteria and management strategies based on early experience and studies for COVID-19-associated coagulopathy thus require re-evaluation. As many other infectious disease states are also associated with hemostatic dysfunction, the coagulopathy associated with COVID-19 may be compounded, especially throughout the winter months, in patients with diverse etiologies of COVID-19 and other infections. This commentary examines what we have learned about COVID-19-associated coagulopathy throughout the pandemic and how we might best prepare to mitigate the hemostatic consequences of emerging infection agents.PMID:38428590 | DOI:10.1016/j.jtha.2024.02.013
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Source Type: research